Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.30), $0.15 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $136.27 million.

GUIDANCE:

Intra-Cellular Therapies sees FY2024 revenue of $645-675 million, versus the consensus of $656.4 million. SG&A expenses (GAAP) $450 - $480. R&D expenses (GAAP) $215 - $240

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.